[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501707":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":25,"locations":33,"responsibleParty":53,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":25,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":25,"overallStatus":35,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vericiguat","ACTIVE_COMPARATOR","10 mg vericiguat administered orally once daily for three days (through day of surgery)",[13],"Drug: Vericiguat",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","placebo administered orally once daily for three days (through day of surgery)",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Vericiguat 10 mg administered orally starting 2 days prior to heart surgery through the day of surgery",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Matched placebo administered orally starting 2 days prior to heart surgery through the day of surgery",[15],[30],{"name":31,"affiliation":5,"role":32},"Marcos Lopez, MD","PRINCIPAL_INVESTIGATOR",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Nashville","Tennessee","37204","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-86.78444,36.16589,{"lat":45,"lon":44},[48],{"name":49,"role":50,"phone":51,"phoneExt":25,"email":52},"Marcos G Lopez, MD","CONTACT","615-936-5894","marcos.g.lopez@vumc.org",{"type":32,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Marcos G. Lopez","Associate Professor of Anesthesiology",[57],{"name":58,"class":59},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100501707","phase-4-sgc-stimulation-perioperative-vascular-reactivity-and-organ-injury-in-cardiac-surgery-100501707",false,"NCT05812755","SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery","The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery","SOLSTICE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Elective open-heart surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy\n\nExclusion Criteria:\n\n1. Intolerance to vericiguat\n2. Use of other soluble guanylyl cyclase stimulators or current use of phosphodiesterase-5 inhibitors\n3. Pregnancy or breast feeding. Pregnancy will be excluded in women of child-bearing potential by a urine or serum beta hcg test\n4. Renal replacement therapy within 30 days prior to screening\n5. Estimated glomerular filtration rate \\\u003C15 ml\u002Fmin per 1.73 m2 per Chronic Kidney Disease Epidemiology collaboration (CKD-EPI) equation at time of screening\n6. Systolic blood pressure less than 120 mmHg at the time of screening\n7. Prior kidney transplantation\n8. History of significant liver dysfunction (defined as Child-Pugh class C)\n9. Surgery scheduled to be performed with circulatory arrest\n10. Surgery scheduled to correct a major congenital heart defect\n11. Extracorporeal membrane oxygenation (ECMO) prior to surgery\n12. Active systemic infection or surgery for infectious endocarditis\n13. Ventricular assist device or intraaortic balloon pump support prior to surgery\n14. Prisoners","ALL","18 Years",{"count":71,"type":72},170,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are:\n\n1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo?\n2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo?\n\nParticipants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury.\n\nThis will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.",[78,79,80,81,82],"Endothelial Dysfunction","Vascular Diseases","Kidney Injury","Brain Disease","Vascular Inflammation","2025-07-02",{"date":85,"type":86},"2025-07-08","ACTUAL",{"date":88,"type":86},"2023-05-19",{"date":90,"type":72},"2027-11",{"name":5,"class":6},1]